The Benefit of Bermekimab in Patients With Systemic Sclerosis
Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimab in Systemic Sclerosis: A Proof- Of-Concept Double-Blind Randomized Clinical Trial (the Light Trial)
Sponsor: Hellenic Institute for the Study of Sepsis
This PHASE2 trial investigates Scleroderma, Systemic and is currently completed. Hellenic Institute for the Study of Sepsis leads this study, which shows 7 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Oct 2022 — Jul 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Feb 2021 — Oct 2022 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2019 — Feb 2020 [monthly]
Recruiting PHASE2
First recorded
Jul 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hellenic Institute for the Study of Sepsis
For direct contact, visit the study record on ClinicalTrials.gov .